<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Shutterstock_2419837881-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Shutterstock_2419837881-430x241.jpg"/></p>
<p>Biocat 的 Montserrat Dabban 呼吁欧洲生物制药的利益相关者通过人工智能驱动的数据分析来实现创新，以此作为未来竞争成功的途径。图片来源：Ivan Marc / Shutterstock.com。</p>
<p>欧洲的生物制药利益相关者应通过人工智能寻求创新，以应对治疗耐药性、药物可负担性和逐渐逼近的专利悬崖等挑战，利用该大陆的健康数据来赶上美国和中国等更具竞争力的行业。</p>
<p>这是 Montserrat Dabban 在 2025 年 CPHI 大会上的主题演讲中阐述的观点，该大会于 10 月 28 日至 30 日在法兰克福举行。Dabban 是 Biocat 的战略前瞻与国际关系主任，该机构是一个支持西班牙加泰罗尼亚医疗生态系统的公私合营实体。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>智能制药 - 主题研究</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>医疗保健中的人工智能（AI）- 主题研究</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>她表示，欧洲生物制药行业的利益相关者可以通过利用健康系统收集的大量数据，使用人工智能找到在多个关键领域应对挑战的创新解决方案，包括 药物发现 和 改进的试验设计。</p>
<p>Dabban 指出，全球生物制药行业今天面临的几个关键挑战，包括物流方面的挑战，如扩大 细胞和基因疗法、提高临床试验速度、药物可负担性，以及 供应链韧性 的不确定性、可持续性和疫情准备。</p>
<p>同时，她指出，行业面临即将到来的 药物专利到期，这可能导致数十亿美元的年度总收入风险：“管道正在变薄……管道增长放缓。”</p>
<p>此外，目前的研究趋势在代谢、免疫和肿瘤疾病的发展上存在不平衡，忽视了其他适应症。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>为了避免 Dabban 所称的 “治疗饱和”——为过少的目标开发过多的分子——她表示，欧洲生物制药的所有利益相关者必须在多个关键领域合作：老龄化人口、脑健康、癌症、抗微生物耐药性、健康公平和罕见疾病。为此，她指出需要扩大对欧洲 广泛健康数据库 的利用。</p>
<p>Dabban 表示，改善对 可穿戴设备 数据的使用可以为数字表型、改进生物标志物和神经学试验中的集中终点打开大门。例如，在肿瘤学中，她建议探索自适应试验和联邦分析，以便可以在不需要集中化的情况下分析来自多个来源的数据。</p>
<p>但 Dabban 告诉与会者，庞大的数据存储 “如果不经过处理就是无用的，我们需要技术来实现这一点”。因此，她表示，人工智能将是有效处理健康数据的关键，以便开发更快的临床试验和更集中化的终点。</p>
<p>“我们正处于一个十字路口。我们必须抓住欧洲的机遇……我们必须预期更多的竞争，但也要期待更多的突破，” Dabban 总结道。</p>
<h2>制药技术卓越奖 - 参赛的好处</h2>
<p>获得应有的认可！制药技术卓越奖 表彰创新、领导力和影响力。通过参赛，您展示了自己的成就，提升了行业形象，并将自己置于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交您的参赛作品！</p>
<p>立即提名</p>

惠普森医药

<p>在 2025 年 CPHI 会议上，Biocat 的 Montserrat Dabban 强调了人工智能驱动的创新在欧洲生物制药行业中的重要性。她呼吁利益相关者利用健康数据来应对治疗抵抗、药物可负担性和专利到期等挑战。Dabban 指出，解决老龄化人口和抗微生物抵抗等问题需要合作，倡导改善来自可穿戴设备和适应性试验的数据利用。她总结道，人工智能对于处理健康数据以增强临床试验和推动行业突破至关重要</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Shutterstock_2419837881-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/Shutterstock_2419837881-430x241.jpg"/></p>
<p>Biocat’s Monserrat Dabban urged stakeholders in European biopharma to see innovation through AI-driven data analytics as the route to future competitive success. Credit: Ivan Marc / Shutterstock.com.</p>
<div class="lb-trans"><p>Biocat 的 Montserrat Dabban 呼吁欧洲生物制药的利益相关者通过人工智能驱动的数据分析来实现创新，以此作为未来竞争成功的途径。图片来源：Ivan Marc / Shutterstock.com。</p>
</div><p>Europe’s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping patent cliff, channelling the continent’s health data to catch up to more competitive industries in the US and China.</p>
<div class="lb-trans"><p>欧洲的生物制药利益相关者应通过人工智能寻求创新，以应对治疗耐药性、药物可负担性和逐渐逼近的专利悬崖等挑战，利用该大陆的健康数据来赶上美国和中国等更具竞争力的行业。</p>
</div><p>This was the view Montserrat Dabban outlined in her keynote address at the 2025 CPHI conference, which took place on 28–30 October in Frankfurt. Dabban is the director of strategic foresight and international relations at Biocat, a public-private entity to support the healthcare ecosystem in Catalonia, Spain.</p>
<div class="lb-trans"><p>这是 Montserrat Dabban 在 2025 年 CPHI 大会上的主题演讲中阐述的观点，该大会于 10 月 28 日至 30 日在法兰克福举行。Dabban 是 Biocat 的战略前瞻与国际关系主任，该机构是一个支持西班牙加泰罗尼亚医疗生态系统的公私合营实体。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Smart Pharma - Thematic Research</h4>
<div class="lb-trans"><h4>智能制药 - 主题研究</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Artificial Intelligence (AI) in Healthcare - Thematic Research</h4>
<div class="lb-trans"><h4>医疗保健中的人工智能（AI）- 主题研究</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>She said that stakeholders in the European biopharma industry could find innovative solutions to challenges in several key areas by using AI to leverage the vast amounts of data collected by health systems for drug discovery and improved trial design.</p>
<div class="lb-trans"><p>她表示，欧洲生物制药行业的利益相关者可以通过利用健康系统收集的大量数据，使用人工智能找到在多个关键领域应对挑战的创新解决方案，包括 药物发现 和 改进的试验设计。</p>
</div><p>Dabban identified several key challenges faced by the global biopharma industry today, including logistical ones like scaling up cell and gene therapies, improving clinical trial speeds, drug affordability, as well as the uncertainties of supply chain resilience, sustainability, and pandemic preparedness.</p>
<div class="lb-trans"><p>Dabban 指出，全球生物制药行业今天面临的几个关键挑战，包括物流方面的挑战，如扩大 细胞和基因疗法、提高临床试验速度、药物可负担性，以及 供应链韧性 的不确定性、可持续性和疫情准备。</p>
</div><p>Meanwhile, she noted the industry faces an oncoming wave of drug patent expiries, risking billions of dollars in total annual revenues: “Pipelines are thinning … pipeline growth slowed.”</p>
<div class="lb-trans"><p>同时，她指出，行业面临即将到来的 药物专利到期，这可能导致数十亿美元的年度总收入风险：“管道正在变薄……管道增长放缓。”</p>
</div><p>Additionally, current research trends have a lopsided focus on development in metabolic, immunological, and oncological diseases at the expense of other indications.</p>
<div class="lb-trans"><p>此外，目前的研究趋势在代谢、免疫和肿瘤疾病的发展上存在不平衡，忽视了其他适应症。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>To avoid the pitfalls of what Dabban termed “therapeutic saturation” — too many molecules developed for too few targets — she said all stakeholders in European biopharma must cooperate in addressing several key domains: aging populations, brain health, cancer, antimicrobial resistance, health equity, and rare disease. To do so, she pointed to upscaling the utilisation of Europe’s extensive health databases.</p>
<div class="lb-trans"><p>为了避免 Dabban 所称的 “治疗饱和”——为过少的目标开发过多的分子——她表示，欧洲生物制药的所有利益相关者必须在多个关键领域合作：老龄化人口、脑健康、癌症、抗微生物耐药性、健康公平和罕见疾病。为此，她指出需要扩大对欧洲 广泛健康数据库 的利用。</p>
</div><p>Dabban said that improved use of data from wearable devices can open the door to digital phenotyping, improved biomarkers, and centralised endpoints in neurological trials. For example, in oncology, she suggested exploring adaptive trials and federated analytics so that data from multiple sources can be analysed without needing to be centralised.</p>
<div class="lb-trans"><p>Dabban 表示，改善对 可穿戴设备 数据的使用可以为数字表型、改进生物标志物和神经学试验中的集中终点打开大门。例如，在肿瘤学中，她建议探索自适应试验和联邦分析，以便可以在不需要集中化的情况下分析来自多个来源的数据。</p>
</div><p>But Dabban told attendees that a vast data store was “useless if it’s not processed, and we need technology for that”. Hence, AI would prove key to effectively processing health data as a means to developing faster clinical trials with more focussed endpoints, she said.</p>
<div class="lb-trans"><p>但 Dabban 告诉与会者，庞大的数据存储 “如果不经过处理就是无用的，我们需要技术来实现这一点”。因此，她表示，人工智能将是有效处理健康数据的关键，以便开发更快的临床试验和更集中化的终点。</p>
</div><p>“We are at a crossroads. We have to seize the moment for Europe … we have to expect more competition, but also more breakthroughs,” Dabban concluded.</p>
<div class="lb-trans"><p>“我们正处于一个十字路口。我们必须抓住欧洲的机遇……我们必须预期更多的竞争，但也要期待更多的突破，” Dabban 总结道。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 参赛的好处</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>获得应有的认可！制药技术卓越奖 表彰创新、领导力和影响力。通过参赛，您展示了自己的成就，提升了行业形象，并将自己置于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交您的参赛作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

CPHI 2025：引导人工智能驱动的创新以发挥欧洲的数据优势